Last $32.91 USD
Change Today -0.33 / -0.99%
Volume 589.0K
PODD On Other Exchanges
As of 8:10 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (PODD) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $51.31
52 Week Low
01/15/15 - $27.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSULET CORP (PODD)

insulet corp (PODD) Related Bloomberg News

View More Bloomberg News

insulet corp (PODD) Related Businessweek News

No Related Businessweek News Found

insulet corp (PODD) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and a handheld, wireless personal diabetes manager. It is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells its OmniPod System directly to patients through referrals from healthcare professionals and through patient leads, as well as through third-party distributors. Insulet Corporation was founded in 2000 and is based in Bedford, Massachusetts.

478 Employees
Last Reported Date: 02/28/14
Founded in 2000

insulet corp (PODD) Top Compensated Officers

Director of Advanced Technology and Director
Total Annual Compensation: $376.9K
General Counsel and Secretary
Total Annual Compensation: $265.0K
Executive Officer
Total Annual Compensation: $306.3K
Compensation as of Fiscal Year 2013.

insulet corp (PODD) Key Developments

Insulet Corporation Announces Executive Appointments

Insulet Corporation announced the appointment of Daniel Levangie to the newly-created role of President, Insulet Drug Delivery, and Ms. Shacey Petrovic to the position of Chief Commercial Officer, both reporting directly to Patrick Sullivan, President and Chief Executive Officer. As President, Insulet Drug Delivery, Mr. Levangie will focus on developing new growth opportunities for use of the OmniPod technology in the administration of a range of pharmaceutical products. In her role as Chief Commercial Officer, Ms. Petrovic will oversee all of the company's commercial operations, including sales, marketing, managed care and business development. These appointments further strengthen the company's senior leadership capabilities.

Insulet Corporation Announces Executive Changes

Insulet Corporation announced that Dr. John Fallon has been appointed Lead Director of the company's Board of Directors. Dr. Fallon has served on the company Board since 2012 and replaces Daniel Levangie who is resigning from the Insulet Board in order to assume the newly-created role of President, Insulet Drug Delivery. Dr. John Fallon has served on the company's Board since October 2012. He also serves on the Board of Directors of AMAG Pharmaceuticals. Since 2004, Dr. Fallon has served as the Chief Physician Executive and Senior Vice President of Blue Cross Blue Shield of Massachusetts. From 2000 to 2004, he held the position of Chief Executive Officer for Clinical Affairs at the State University of New York Medical Center. In 1995, Dr. Fallon became a founding Trustee of Partners Community HealthCare Inc. he went on to become Chairman of PCHI. Dr. Fallon has also served as Founder, President and Chief Executive Officer of North Shore Health System, Chief Medical Executive and later Chief Executive Officer of Charter Professional Services Corporation, and First Chief Medical Officer for North Shore Medical Center. Dr. Fallon has over 35 years of experience as a practicing physician, senior executive and participant in numerous medical boards and committees in the health care industry.

Insulet Corporation to Report Q4, 2014 Results on Feb 26, 2015

Insulet Corporation announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 26, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $32.91 USD -0.33

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $148.54 USD +0.43
DexCom Inc $61.96 USD -1.38
Smiths Group PLC 1,157 GBp +7.00
Takeda Pharmaceutical Co Ltd ¥6,123 JPY +15.00
Tandem Diabetes Care Inc $12.24 USD -0.58
View Industry Companies

Industry Analysis


Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 23.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at